Overview
Jose Ruiz is a Hematologist Oncology specialist and a Hematologist in Fayetteville, North Carolina. Dr. Ruiz has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Angiosarcoma, and Familial Colorectal Cancer. Dr. Ruiz is currently accepting new patients.
His clinical research consists of co-authoring 2 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- INSURANCE PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- MANAGED MEDICAID PLAN
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
6387 Ramsey Street, Fayetteville, NC 28311
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Duke Cancer Center
When someone is faced with a diagnosis of lung cancer, they may be going through surgery, radiation treatment, chemotherapy or enrolling in a clinical trial. It’s a very complicated process to understand what’s involved and what may happen next. It’s also hard to hear all the answers if you’re by yourself. We encourage our patients to come with family members and friends and loved ones and particularly to identify one or two main go-to people in terms of care-giving and support. That way we can engage them in the whole process. Just as we have a team taking care of the patient, the patient has a team, too. At Duke, we have the opportunity to engage patients in the very latest treatment approaches, whether it’s a new surgical technique, the latest radiation approach, or some novel chemotherapy, immunology, or targeted therapy, several of which we’ve been developing. Duke provides patients with a real opportunity that they may not have elsewhere. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and ALK-Positive Non-Small Cell Lung Cancer.
Wakemed Specialists Group LLC
Praveen Namireddy is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Namireddy is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Namireddy is currently accepting new patients.
Duke Cancer Center
I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- AngiosarcomaDr. Ruiz isDistinguished. Learn about Angiosarcoma.
- Familial Colorectal CancerDr. Ruiz isDistinguished. Learn about Familial Colorectal Cancer.
- Lung AdenocarcinomaDr. Ruiz isDistinguished. Learn about Lung Adenocarcinoma.
- Small Cell Lung Cancer (SCLC)Dr. Ruiz isDistinguished. Learn about Small Cell Lung Cancer (SCLC).
- Undifferentiated Pleomorphic SarcomaDr. Ruiz isDistinguished. Learn about Undifferentiated Pleomorphic Sarcoma.
- Advanced
- Acquired HemophiliaDr. Ruiz isAdvanced. Learn about Acquired Hemophilia.
- Adult Soft Tissue SarcomaDr. Ruiz isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- ALK-Positive Non-Small Cell Lung Cancer
- Anal CancerDr. Ruiz isAdvanced. Learn about Anal Cancer.
- Bone TumorDr. Ruiz isAdvanced. Learn about Bone Tumor.
- Breast CancerDr. Ruiz isAdvanced. Learn about Breast Cancer.
- Experienced
- Acinic Cell Carcinoma of Salivary Glands
- Acute Mountain SicknessDr. Ruiz isExperienced. Learn about Acute Mountain Sickness.
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Ruiz isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Adenoid Cystic CarcinomaDr. Ruiz isExperienced. Learn about Adenoid Cystic Carcinoma.

